Key Points. Epcoritamab, a CD3xCD20 bispecific antibody, plus GemOx yields deep, durable responses in second-line or later ASCT-ineligible R/R DLBCLHigher
Dr. Ravi Salgia is an oncologist at City of Hope cancer center. When he and his wife and adult daughter were evacuated from their Pasadena…
Erman Akkus: KRAS mutations in pancreatic cancer / Adenocarcinoma, Amanda Erakky, Amanda Zucker, Anna M. Varghese, cancer, Daniel Muldoon, Erman Akkus, Joanne
This Review describes why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of central nervous system tumors.
This Viewpoint discusses strategies used with driving that can be applied to health care to promote consistent and predictable physician and patient actions.
Research To Practice requires users to log in to view educational content. All content is available without
This cohort study examines if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.
PURPOSEThe clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A…
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell…
Nature Medicine – In the final report of a phase 1 trial evaluating intracerebroventricular B7-H3-targeting CAR T cells in children and young adults with diffuse…
PURPOSEFinancial toxicity (FT) of cancer treatment likely affects more patients in low- and middle-income countries (LMICs); however, most of the research on FT comes from…
